Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Richard M. Stone, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Richard Stone and Amir Fathi.
Richard Stone
Connection Strength
2.075
Amir Fathi
  1. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 02 13; 135(7):463-471.
    View in: PubMed
    Score: 0.215
  2. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.212
  3. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549.
    View in: PubMed
    Score: 0.197
  4. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
    View in: PubMed
    Score: 0.165
  5. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012 Nov 29; 120(23):4649-52.
    View in: PubMed
    Score: 0.129
  6. A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. Blood Adv. 2021 04 27; 5(8):2279-2283.
    View in: PubMed
    Score: 0.058
  7. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 04 01; 137(13):1792-1803.
    View in: PubMed
    Score: 0.058
  8. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021 01 06; 19(1):16-27.
    View in: PubMed
    Score: 0.057
  9. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021 01 01; 39(1):57-65.
    View in: PubMed
    Score: 0.056
  10. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. Blood Adv. 2020 05 12; 4(9):1894-1905.
    View in: PubMed
    Score: 0.055
  11. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr; 7(4):e309-e319.
    View in: PubMed
    Score: 0.054
  12. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
    View in: PubMed
    Score: 0.052
  13. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687.
    View in: PubMed
    Score: 0.051
  14. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 06 01; 17(6):721-749.
    View in: PubMed
    Score: 0.051
  15. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
    View in: PubMed
    Score: 0.050
  16. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 02 14; 133(7):676-687.
    View in: PubMed
    Score: 0.049
  17. Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018 09; 93(9):1119-1126.
    View in: PubMed
    Score: 0.049
  18. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
    View in: PubMed
    Score: 0.048
  19. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398.
    View in: PubMed
    Score: 0.048
  20. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
    View in: PubMed
    Score: 0.047
  21. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.046
  22. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 07; 15(7):926-957.
    View in: PubMed
    Score: 0.045
  23. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 08 10; 130(6):722-731.
    View in: PubMed
    Score: 0.045
  24. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):60-87.
    View in: PubMed
    Score: 0.043
  25. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
    View in: PubMed
    Score: 0.042
  26. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
    View in: PubMed
    Score: 0.041
  27. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
    View in: PubMed
    Score: 0.039
  28. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):261-72.
    View in: PubMed
    Score: 0.038
  29. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.